Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther September 1 2018 17 (9) 1793-1793;

Reviews

  • Reviews
    Strategies to Address Chimeric Antigen Receptor Tonic Signaling
    Adam Ajina and John Maher
    Mol Cancer Ther September 1 2018 17 (9) 1795-1815; DOI:10.1158/1535-7163.MCT-17-1097

  • Reviews
    Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer
    Lin Zhang, Dan Peng, Anil K. Sood, Chi V. Dang and Xiaomin Zhong
    Mol Cancer Ther September 1 2018 17 (9) 1816-1823; DOI:10.1158/1535-7163.MCT-18-0124

  • Reviews
    We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine
    Kathryn M. Lemberg, James J. Vornov, Rana Rais and Barbara S. Slusher
    Mol Cancer Ther September 1 2018 17 (9) 1824-1832; DOI:10.1158/1535-7163.MCT-17-1148

Small Molecule Therapeutics

  • Small Molecule Therapeutics
    AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
    Kshitij Verma, Nehal Gupta, Tianzhu Zang, Phumvadee Wangtrakluldee, Sanjay K. Srivastava, Trevor M. Penning and Paul C. Trippier
    Mol Cancer Ther September 1 2018 17 (9) 1833-1845; DOI:10.1158/1535-7163.MCT-17-1023

  • Small Molecule Therapeutics
    Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity In Vitro and Tissue Selectivity In Vivo
    D. Alwyn Dart, Sahar Kandil, Serena Tommasini-Ghelfi, Gilberto Serrano de Almeida, Charlotte L. Bevan, Wenguo Jiang and Andrew D. Westwell
    Mol Cancer Ther September 1 2018 17 (9) 1846-1858; DOI:10.1158/1535-7163.MCT-18-0037

  • Small Molecule Therapeutics
    Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer
    Yang Yang, Kenza Mamouni, Xin Li, Yanhua Chen, Sravan Kavuri, Yuhong Du, Haian Fu, Omer Kucuk and Daqing Wu
    Mol Cancer Ther September 1 2018 17 (9) 1859-1870; DOI:10.1158/1535-7163.MCT-17-1176

  • Small Molecule Therapeutics
    Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells
    Rui Wang, Ying Li, Ping Gong, Janice Gabrilove, Samuel Waxman and Yongkui Jing
    Mol Cancer Ther September 1 2018 17 (9) 1871-1880; DOI:10.1158/1535-7163.MCT-17-0298

  • Small Molecule Therapeutics
    A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
    Maria Cristina Manara, Sergio Valente, Camilla Cristalli, Giordano Nicoletti, Lorena Landuzzi, Clemens Zwergel, Roberta Mazzone, Giulia Stazi, Paola B. Arimondo, Michela Pasello, Clara Guerzoni, Piero Picci, Patrizia Nanni, Pier-Luigi Lollini, Antonello Mai and Katia Scotlandi
    Mol Cancer Ther September 1 2018 17 (9) 1881-1892; DOI:10.1158/1535-7163.MCT-17-0818

  • Small Molecule Therapeutics
    Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
    Minjee Kim, Daniel J. Ma, David Calligaris, Shuangling Zhang, Ryan W. Feathers, Rachael A. Vaubel, Isabelle Meaux, Ann C. Mladek, Karen E. Parrish, Fang Jin, Cedric Barriere, Laurent Debussche, James Watters, Shulan Tian, Paul A Decker, Jeanette E. Eckel-Passow, Gaspar J. Kitange, Aaron J. Johnson, Ian F. Parney, Panos Z. Anastasiadis, Nathalie Y.R. Agar, William F. Elmquist and Jann N. Sarkaria
    Mol Cancer Ther September 1 2018 17 (9) 1893-1901; DOI:10.1158/1535-7163.MCT-17-0600

  • Small Molecule Therapeutics | AuthorChoice
    Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
    Kathleen I. Pishas, Christina D. Drenberg, Cenny Taslim, Emily R. Theisen, Kirsten M. Johnson, Ranajeet S. Saund, Ioana L. Pop, Brian D. Crompton, Elizabeth R. Lawlor, Franck Tirode, Jaume Mora, Olivier Delattre, Mary C. Beckerle, David F. Callen, Sunil Sharma and Stephen L. Lessnick
    Mol Cancer Ther September 1 2018 17 (9) 1902-1916; DOI:10.1158/1535-7163.MCT-18-0373

Large Molecule Therapeutics

  • Large Molecule Therapeutics | AuthorChoice
    STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer
    Christian Njatcha, Mariya Farooqui, Adam Kornberg, Daniel E. Johnson, Jennifer R. Grandis and Jill M. Siegfried
    Mol Cancer Ther September 1 2018 17 (9) 1917-1926; DOI:10.1158/1535-7163.MCT-17-1194

  • Large Molecule Therapeutics | AuthorChoice
    Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
    Wilhem Leconet, He Liu, Ming Guo, Sophie Le Lamer-Déchamps, Charlotte Molinier, Sae Kim, Tjasa Vrlinic, Murielle Oster, Fang Liu, Vicente Navarro, Jaspreet S. Batra, Adolfo Lopez Noriega, Sylvestre Grizot and Neil H. Bander
    Mol Cancer Ther September 1 2018 17 (9) 1927-1940; DOI:10.1158/1535-7163.MCT-17-1138

  • Large Molecule Therapeutics
    Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell–Mediated Antitumor Immunity By Suppressing PD-L1
    Satoshi Nakagawa, Satoshi Serada, Reisa Kakubari, Kosuke Hiramatsu, Takahito Sugase, Shinya Matsuzaki, Satoko Matsuzaki, Yutaka Ueda, Kiyoshi Yoshino, Tomoharu Ohkawara, Minoru Fujimoto, Tadamitsu Kishimoto, Tadashi Kimura and Tetsuji Naka
    Mol Cancer Ther September 1 2018 17 (9) 1941-1950; DOI:10.1158/1535-7163.MCT-17-0822

  • Large Molecule Therapeutics
    Recombinant MDA-7/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt/Mcl-1 Pathway
    Anjan K. Pradhan, Praveen Bhoopathi, Sarmistha Talukdar, Xue-Ning Shen, Luni Emdad, Swadesh K. Das, Devanand Sarkar and Paul B. Fisher
    Mol Cancer Ther September 1 2018 17 (9) 1951-1960; DOI:10.1158/1535-7163.MCT-17-1002

  • Large Molecule Therapeutics | AuthorChoice
    Leukocyte Differentiation by Histidine-Rich Glycoprotein/Stanniocalcin-2 Complex Regulates Murine Glioma Growth through Modulation of Antitumor Immunity
    Francis P. Roche, Ilkka Pietilä, Hiroshi Kaito, Elisabet O. Sjöström, Nadine Sobotzki, Oriol Noguer, Tor Persson Skare, Magnus Essand, Bernd Wollscheid, Michael Welsh and Lena Claesson-Welsh
    Mol Cancer Ther September 1 2018 17 (9) 1961-1972; DOI:10.1158/1535-7163.MCT-18-0097

Cancer Biology and Translational Studies

  • Cancer Biology and Translational Studies
    KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer
    Wenyu Wang, Keng Gat Lim, Min Feng, Yi Bao, Puay Leng Lee, Yu Cai, Yufeng Chen, Hao Zhang, Diego Marzese, Dave S.B. Hoon and Qiang Yu
    Mol Cancer Ther September 1 2018 17 (9) 1973-1983; DOI:10.1158/1535-7163.MCT-17-0802

  • Cancer Biology and Translational Studies
    Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
    Andrew M. Donson, Vladimir Amani, Elliot A. Warner, Andrea M. Griesinger, Davis A. Witt, Jean M. Mulcahy Levy, Lindsey M. Hoffman, Todd C. Hankinson, Michael H. Handler, Rajeev Vibhakar, Kathleen Dorris and Nicholas K. Foreman
    Mol Cancer Ther September 1 2018 17 (9) 1984-1994; DOI:10.1158/1535-7163.MCT-17-1185

  • Cancer Biology and Translational Studies
    Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease
    Ananda Mukherjee, Amanda L. Patterson, Jitu W. George, Tyler J. Carpenter, Zachary B. Madaj, Galen Hostetter, John I. Risinger and Jose M. Teixeira
    Mol Cancer Ther September 1 2018 17 (9) 1995-2003; DOI:10.1158/1535-7163.MCT-17-1255

  • Cancer Biology and Translational Studies
    The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance
    Benjamin L. Woolbright, Dharamainder Choudhary, Andrew Mikhalyuk, Cassandra Trammel, Sambantham Shanmugam, Erika Abbott, Carol C. Pilbeam and John A. Taylor III
    Mol Cancer Ther September 1 2018 17 (9) 2004-2012; DOI:10.1158/1535-7163.MCT-18-0063

  • Cancer Biology and Translational Studies | AuthorChoice
    Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma
    Paul L. Feingold, Deborah R. Surman, Kate Brown, Yuan Xu, Lucas A. McDuffie, Vivek Shukla, Emily S. Reardon, Daniel R. Crooks, Jane B. Trepel, Sunmin Lee, Min-Jung Lee, Shaojian Gao, Sichuan Xi, Kaitlin C. McLoughlin, Laurence P. Diggs, David G. Beer, Derek J. Nancarrow, Leonard M. Neckers, Jeremy L. Davis, Chuong D. Hoang, Jonathan M. Hernandez, David S. Schrump and R. Taylor Ripley
    Mol Cancer Ther September 1 2018 17 (9) 2013-2023; DOI:10.1158/1535-7163.MCT-17-1240

  • Cancer Biology and Translational Studies | AuthorChoice
    Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
    Dong Hoon Shin, Jeong Yeon Jo and Ji-Youn Han
    Mol Cancer Ther September 1 2018 17 (9) 2024-2033; DOI:10.1158/1535-7163.MCT-17-1178

  • Cancer Biology and Translational Studies
    Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells
    Xin Xin Quan, Nga Voong Hawk, Weiping Chen, Jamie Coupar, Steven K. Lee, David W. Petersen, Paul S. Meltzer, Andrew Montemarano, Martin Braun, Zhong Chen and Carter Van Waes
    Mol Cancer Ther September 1 2018 17 (9) 2034-2048; DOI:10.1158/1535-7163.MCT-17-0421

  • Cancer Biology and Translational Studies
    Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor
    Shilpa Bhatia, Anastacia Griego, Shelby Lennon, Ayman Oweida, Jaspreet Sharma, Christina Rohmer, Nomin Uyanga, Sanjana Bukkapatnam, Benjamin Van Court, David Raben, Christian Young, Lynn Heasley and Sana D. Karam
    Mol Cancer Ther September 1 2018 17 (9) 2049-2059; DOI:10.1158/1535-7163.MCT-17-1163

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
    Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy
    Tatiana Lepikhova, Piia-Riitta Karhemo, Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, Mikko Kivento, Harri Sihto, Reidar Grénman, Stina M. Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu and Outi Monni
    Mol Cancer Ther September 1 2018 17 (9) 2060-2071; DOI:10.1158/1535-7163.MCT-17-0733

Retractions

  • Retractions | Free Article
    Retraction: γ-Tocotrienol Promotes TRAIL-Induced Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase/p53–Mediated Upregulation of Death Receptors
    Mol Cancer Ther September 1 2018 17 (9) 2072-2072; DOI:10.1158/1535-7163.MCT-18-0869

  • Retractions | Free Article
    Retraction: Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins
    Mol Cancer Ther September 1 2018 17 (9) 2073-2073; DOI:10.1158/1535-7163.MCT-18-0870

  • Retractions | Free Article
    Retraction: Coronarin D, a Labdane Diterpene, Inhibits both Constitutive and Inducible Nuclear Factor-κB Pathway Activation, Leading to Potentiation of Apoptosis, Inhibition of Invasion, and Suppression of Osteoclastogenesis
    Mol Cancer Ther September 1 2018 17 (9) 2074-2074; DOI:10.1158/1535-7163.MCT-18-0871

  • Retractions | Free Article
    Retraction: Potentiation of Paclitaxel Activity by the HSP90 Inhibitor 17-allylamino-17-demethoxygeldanamycin in Human Ovarian Carcinoma Cell Lines with High Levels of Activated AKT
    Mol Cancer Ther September 1 2018 17 (9) 2075-2075; DOI:10.1158/1535-7163.MCT-18-0595

Back to top
PreviousNext
Molecular Cancer Therapeutics: 17 (9)
September 2018
Volume 17, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Issue Highlights

  • Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
  • Strategies to Address Chimeric Antigen Receptor Tonic Signaling
  • STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer
  • KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Jump to

  • Highlights
  • Reviews
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Cancer Biology and Translational Studies
  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
  • Retractions
Advertisement
  • Most Cited
  • Most Read
Loading
  • HDAC Inhibition Benefits ARID1A-Mutated Bladder Cancer
  • MERTK Inhibition Suppresses Melanoma Tumor Growth
  • Antibody–Cytokine Fusions against CAIX
  • Peptide Antagonist of PD-1 Signaling Pathway
  • Targeting PI3K/AKT/mTOR Pathway in Pancreatic Cancer
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement